Search

Search Constraints

You searched for: Author/Creator Schobel, Scott

Search Results

2. F61 Digital, high-frequency, long-term monitoring of motor and non-motor symptoms in huntington's disease (hd) patients. (September 2018)

3. J02 A global development program testing RG6042, an anti-sense oligonucleotide, for the treatment of early manifest huntington's disease (hd). (September 2018)

5. J01 Effects of IONIS-HTTRX (RG6042) in patients with early huntington's disease, results of the first htt-lowering drug trial. (September 2018)

6. D09 Parallel evaluation of mutant huntingtin and neurofilament light as biomarkers for huntington's disease: the hd-csf study. (September 2018)

7. 241  Intrathecal antisense oligonucleotide delivery in HD: experience from RG6042 programme and best practice considerations. Issue 6 (27th May 2022)

8. A biological classification of Huntington's disease: the Integrated Staging System. Issue 7 (July 2022)

9. Linking amyloid to clinical outcome: A quantitative semi‐mechanistic model based on the A/T/N biomarker framework to simulate the natural history of Alzheimer's disease and the effects of anti‐amyloid treatment. (20th December 2022)

10. Results and evaluation of a first‐in‐human study of RG7342, an mGlu5 positive allosteric modulator, utilizing Bayesian adaptive methods. (18th December 2017)